Poolbeg Pharma (LON:POLB) Stock Price Up 5.2% – Here’s Why

Poolbeg Pharma PLC (LON:POLB)’s stock price shot up 5.2% during trading on Wednesday . The company traded as high as GBX 8.10 ($0.11) and last traded at GBX 8.10 ($0.11). 475,472 shares were traded during mid-day trading, a decline of 73% from the average session volume of 1,772,456 shares. The stock had previously closed at GBX 7.70 ($0.10).

Poolbeg Pharma Stock Performance

The company has a market cap of £42.06 million, a P/E ratio of -841.20 and a beta of 2.11. The business has a fifty day simple moving average of GBX 9.65 and a 200 day simple moving average of GBX 11.64.

About Poolbeg Pharma

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.